TY  - JOUR
AU  - Cortés-Ibáñez, Francisco O
AU  - Johnson, Theron
AU  - Mascalchi, Mario
AU  - Katzke, Verena
AU  - Delorme, Stefan
AU  - Kaaks, Rudolf
TI  - Cardiac troponin I as predictor for cardiac and other mortality in the German randomized lung cancer screening trial (LUSI).
JO  - Scientific reports
VL  - 14
IS  - 1
SN  - 2045-2322
CY  - [London]
PB  - Macmillan Publishers Limited, part of Springer Nature
M1  - DKFZ-2024-00610
SP  - 7197
PY  - 2024
N1  - #EA:C020#LA:C020#
AB  - Cardiac Troponin I (cTnI) could be used to identify individuals at elevated risk of cardiac death in lung cancer (LC) screening settings. In a population-based, randomized LC screening trial in Germany ('LUSI' study) serum cTnI was measured by high-sensitivity assay in blood samples collected at baseline, and categorized into unquantifiable/low (< 6 ng/L), intermediate (≥ 6-15 ng/L), and elevated (≥ 16 ng/L). Cox proportional-hazard models were used to estimate risk of all-cause and cardiac mortality with cTnI levels. After exclusion criteria, 3653 participants were included for our analyses, of which 82.4
KW  - Biomarkers (Other)
KW  - Lung cancer screening (Other)
KW  - Mortality (Other)
KW  - Myocardial infarction (Other)
KW  - Risk assessment (Other)
KW  - Troponin (Other)
LB  - PUB:(DE-HGF)16
C6  - pmid:38531926
DO  - DOI:10.1038/s41598-024-57889-z
UR  - https://inrepo02.dkfz.de/record/289143
ER  -